User profiles for K. Pavenski
Katerina PavenskiSt. Michael's Hospital, University of Toronto Verified email at smh.ca Cited by 4463 |
HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management
Approximately five decades ago, alloimmunization to human leukocyte antigens (HLA) and
platelet refractoriness were recognized as potentially serious complications of platelet …
platelet refractoriness were recognized as potentially serious complications of platelet …
Redefining outcomes in immune TTP: an international working group consensus report
…, K Pavenski, F Peyvandi, K Sakai… - Blood, The Journal …, 2021 - ashpublications.org
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic
microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. …
microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. …
Compliance with a massive transfusion protocol (MTP) impacts patient outcome
…, N Ahmed, H Izadi, A McFarlan, A Nathens, K Pavenski - Injury, 2015 - Elsevier
Background About 5% of civilian trauma requires massive transfusion. Protocolized resuscitation
with blood products to achieve high plasma:RBC ratio has been advocated to improve …
with blood products to achieve high plasma:RBC ratio has been advocated to improve …
[HTML][HTML] Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
…, A Metjian, J de la Rubia, K Pavenski… - … England Journal of …, 2019 - Mass Medical Soc
Background In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …
Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference
Importance Blood transfusion is one of the most frequently used therapies worldwide and is
associated with benefits, risks, and costs. Objective To develop a set of evidence-based …
associated with benefits, risks, and costs. Objective To develop a set of evidence-based …
[HTML][HTML] Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
…, B Lämmle, M Matsumoto, K Pavenski… - Journal of thrombosis …, 2017 - Elsevier
… K. Pavenski reports receiving honoraria from Alexion Inc., outside the submitted work. B.
Lämmle reports receiving grants from Baxter Biosciences and personal fees from Baxalta, …
Lämmle reports receiving grants from Baxter Biosciences and personal fees from Baxalta, …
Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial
…, S Brar, J Bussières, H Grocott, C Harle, K Pavenski… - Jama, 2019 - jamanetwork.com
Importance Excessive bleeding is a common complication of cardiac surgery. An important
cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which …
cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which …
Red blood cell transfusion: 2023 AABB international guidelines
Importance Red blood cell transfusion is a common medical intervention with benefits and
harms. Objective To provide recommendations for use of red blood cell transfusion in adults …
harms. Objective To provide recommendations for use of red blood cell transfusion in adults …
Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia
…, SJ Slichter, S Tanael, P Rebulla, K Pavenski… - Transfusion medicine …, 2015 - Elsevier
… Slichter b , Susano Tanael c , Paolo Rebulla d , Katerina Pavenski e , Ralph Vassallo f , Mark
Fung g , Rene Duquesnoy h , … HLA-selected platelet transfusion Pavenski et al [24] 1 29 …
Fung g , Rene Duquesnoy h , … HLA-selected platelet transfusion Pavenski et al [24] 1 29 …
Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD
…, M Sholzberg, PS Shah, K Pavenski… - Journal of the …, 2014 - journals.lww.com
Novel oral anticoagulants (NOACs)(rivaroxaban, dabigatran, apixaban) have been approved
by international regulatory agencies to treat atrial fibrillation and venous thromboembolism …
by international regulatory agencies to treat atrial fibrillation and venous thromboembolism …